Heloísa Galante

Heloísa Galante

Auto-generated profile, based on publicly available information

Heloísa Galante

Centre for Health Evaluation & Research/Infosaúde, National Association of Pharmacies (CEFAR/IS-ANF), Rua Marechal Saldanha 1, 1249-069 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MRMariana Romão
Mariana Romão
DFDébora Figueira
Débora Figueira
HGHeloísa Galante
Heloísa Galante
JGJosé Guerreiro
José Guerreiro
SRSónia Romano
Sónia Romano
Background: In 2017, ostomy patients gained access to ostomy products in community pharmacies that are fully reimbursed by the Portuguese National Health Service. This impacted the daily lives of people with ostomy and opened a new market of products and services for pharmacies. However, little is known about the sociodemographic and clinical profile of ostomy patients. This study aims to characterize people with ostomy and their caregivers, evaluate access and satisfaction with the pharmacy and explore participants’ expectations regarding services and counselling.Methods: This was an observational, cross-sectional, multicentre study involving pharmacy users who acquired ostomy products in Portuguese community pharmacies. Data were collected through a confidential self-report questionnaire between June and August 2019.Results: Approximately 56% of the participants were ostomy patients, of whom 65.9% were men. The average age of participating ostomy patients was 65.5 years old (SD = 12.9), and near 80% were retired/pensioners. Caregivers were mostly women (81.7%). More than half of the caregivers were employed and acquired products for a direct family member. Three in every four surgical interventions were consequences of cancer. Intestinal ostomy was the most common intervention (78.3%). More than 93% were satisfied with the acquisition of ostomy products at the pharmacy. Approximately 48.2% of ostomy patients received care from a specialized nurse.Conclusion: This study describes the profile of people with ostomy and their caregivers who attend community pharmacies in Portugal. Participants’ perceptions of the utility of different proposed services and pharmacist knowledge, as well as the low coverage of ostomy nursing care, highlight the opportunity for an extended role of pharmacists among this group.

6 May 2023 in Primary Care Diabetes
Verified
Journal Article
Closed access
RMRodrigo Murteira
Rodrigo Murteira
MCMaria Cary
Maria Cary
HGHeloísa Galante
Heloísa Galante
SRSónia Romano
Sónia Romano
JGJosé Pedro Guerreiro
José Pedro Guerreiro
ARAntónio Teixeira Rodrigues
António Teixeira Rodrigues

19 January 2022 in Value in Health
Verified
Journal Article
Closed access
RMR Murteira
R Murteira
SRS Romano
S Romano
ITInaian Teixeira
Inaian Teixeira
HGH Galante
H Galante
SSS Sousa
S Sousa
ARA Teixeira Rodrigues
A Teixeira Rodrigues

3 April 2022 in Clinical Complementary Medicine and Pharmacology
Verified
Journal Article
Open access
EREdna Ribeiro
Edna Ribeiro
MDMariana Delgadinho
Mariana Delgadinho
EMElisabete Matos
Elisabete Matos
RSRaquel Santos
Raquel Santos
DSDaniela Sousa
Daniela Sousa
Miguel BritoMiguel Brito
Miguel Brito
Background β-hemoglobinopathies are one of the most common recessive genetic diseases worldwide, with limited treatments available, particularly in developed countries where the prevalence is higher. Pharmacological reactivation of Fetal Hemoglobin (HbF) is a promising therapeutic strategy. However, approximately 25% of the patients do not respond to Hydroxyurea (HU), the first and most commonly used HbF inducing agent approved by the FDA. Objective Here, we performed an in vitro assessment of transcriptional effects induced by natural bioactive compounds, namely Epigallocatechin-3-gallate (EGCG) and genistein (GN) in globin genes (HBA1, HBB, HBG1 and HBG2) in HbF regulators/silencer genes (KLF1, BCL11A, MYB and BGLT3) and in epigenetic regulator genes (DNMT1, DNMT3A, DNMT3B, HDAC1, HDAC2, HDAC3 and HDAC8). Moreover, we evaluated EGCG’s in vivo effects in hematological parameters of healthy volunteers. Methods K562 cells were exposed for 72 and 96 h to GN and EGCG at 100, 250 and 500 ng/mL. Cell proliferation and viability were measured, and transcriptional levels were evaluated by qRT-PCR. For in vivo assay, complete blood count was determined by flow cytometry and HbF level was determined through HPLC in 30 healthy individuals before and after 225 mg EGCG ingestion per day during a 90-day period. Results Both compounds impact cellular metabolism and proliferation with no cytotoxic effects. Divergent GN and EGCG effects in globin and BGLT3 expression levels suggest the involvement of divergent signaling pathways. As for the epigenetic potential, EGCG particularly affects HDAC2 and HDAC8 transcription, whereas GN significantly affects expression patterns of methylation and acetylation modulators. HU appears to have time divergent effects, with greater impact in methylation at 72 h (overregulates DNTM3A) while affecting acetylation mostly at 96 h (downregulates HDAC1 and HDAC8). Additionally, in vivo, EGCG demonstrated a modulator effect in hematopoiesis and HbF induction. Conclusion Our results advocate EGCG and GN with HbF pharmacological reactivation potential and sustain further research as new alternative approaches for β-hemoglobinopathies therapies.